Shares of cancer treatment company Juno Therapeutics Inc. jumped 46 percent in their stock market debut Friday.

Share story

Shares of cancer treatment company Juno Therapeutics Inc. jumped 46 percent in their stock market debut Friday.

Juno genetically engineers a patient’s own white blood cells to find and kill cancer cells in the body. In its clinical trials, the company said the treatment showed evidence of tumors shrinking.

The Seattle-based company raised $264.5 million after selling more than 11 million shares at $24 per share. It plans to use the cash raised to continue trials and studies. The stock is listed on the Nasdaq stock market under ticker symbol “JUNO.”

The stock rose $11 to close at $35, after rising as high as $39.50 earlier.